Phathom Pharmaceuticals Announces FDA Acceptance Of NDA Resubmission For Erosive GERD
Portfolio Pulse from Benzinga Newsdesk
Phathom Pharmaceuticals announced that the FDA has accepted its NDA resubmission for vonoprazan, a treatment for Erosive GERD. The FDA classified it as a Class 2 resubmission and assigned a PDUFA goal date of November 17, 2023.
June 12, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phathom Pharmaceuticals' NDA resubmission for vonoprazan has been accepted by the FDA, potentially leading to approval for the Erosive GERD treatment.
The FDA's acceptance of Phathom Pharmaceuticals' NDA resubmission for vonoprazan is a positive development for the company. This increases the likelihood of the drug being approved for the treatment of Erosive GERD, which could lead to increased revenues and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100